Stocks Health care VSTM
NASDAQ · Health careVerastem, Inc. (VSTM)
It posted a net loss of $178.9M. At September 30, 2026 it held $172.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Verastem, Inc.
- Net worth
- Verastem, Inc. has a market value (market cap) of $790.6M at the latest share price, and shareholders' equity of $10.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $30.9M (+209.1% year on year), with a net loss of $209.5M.
- Cash flow
- In fiscal 2025 operations used $137.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Verastem, Inc.'s next report is expected around February 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Verastem, Inc. does
Verastem, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VSTM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $30.9M | -$209.5M | -$3.02 | n/a |
| 2024 | $10M | -$130.6M | -$3.66 | -$104.8M |
| 2023 | n/a | -$87.4M | -$3.96 | n/a |
| 2022 | $2.6M | -$73.8M | -$4.57 | n/a |
| 2021 | $2.1M | -$71.2M | -$4.90 | -$53.7M |
| 2020 | $88.5M | -$67.7M | -$5.26 | -$33.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VSTM ranks in Health care
Latest SEC filings
What Verastem, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- November 5, 2026
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 114% to $24M versus the same quarter last year; diluted EPS -$0.74 versus -$1.35.
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- October 14, 2026Other event 8-K
- October 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026
- August 6, 2026
Insider trades
What the people running Verastem, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $386.4K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Paterson DanPresident and CEO, Director | Soldpre-planned (10b5-1) | 1,299 | $12.5K |
| October 1, 2026 | Calkins DanielChief Financial Officer | Soldpre-planned (10b5-1) | 2,566 | $20.5K |
| October 1, 2026 | Paterson DanPresident and CEO, Director | Soldpre-planned (10b5-1) | 44,121 | $353K |
| September 30, 2026 | Calkins DanielChief Financial Officer | Received as pay | 8,333 | - |
| September 30, 2026 | Paterson DanPresident and CEO, Director | Received as pay | 106,893 | - |
| September 21, 2026 | Calkins DanielChief Financial Officer | Soldpre-planned (10b5-1) | 55 | $423.5 |
| August 3, 2026 | Paterson DanPresident and CEO, Director | Soldpre-planned (10b5-1) | 1,302 | $7.6K |
| June 22, 2026 | Calkins DanielChief Financial Officer | Soldpre-planned (10b5-1) | 4,032 | $16.9K |
Who owns VSTM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Deep Track Capital, LP13G, passive with 2 related filers | 9.99% | November 21, 2025 |
| RTW Investments, LP13G, passive with 1 related filers | 9.9% | May 15, 2026 |
| Armistice Capital, LLC13G, passive with 1 related filers | 7.76% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.03% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 158 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 9,192,447 | +2,997,522 |
| Nantahala Capital Management, LLC | 7,169,640 | +3,584,820 |
| Armistice Capital, LLC | 7,024,000 | +2,432,000 |
| Rtw Investments, LP | 6,635,793 | +59,487 |
| Deep Track Capital, LP | 5,740,850 | 0 |
| State Street Corp | 5,133,859 | +1,617,208 |
| Rosalind Advisors, Inc. | 3,986,509 | +1,848,034 |
| Vanguard Capital Management LLC | 3,851,508 | +528,738 |
| Stonepine Capital Management, LLC | 3,349,627 | +47,327 |
| Vanguard Portfolio Management LLC | 3,266,870 | +2,509,995 |
| Foresite Capital Management VI LLC | 3,146,631 | 0 |
| Goldman Sachs Group Inc | 2,721,178 | +1,237,175 |
| Baker Bros. Advisors LP | 2,499,338 | +1,914,581 |
| Alyeska Investment Group, L.P. | 2,289,625 | +239,625 |
| Millennium Management LLC | 2,078,003 | -333,962 |
| Geode Capital Management, LLC | 2,074,145 | +356,588 |
| AIGH Capital Management LLC | 1,927,000 | -73,000 |
| Opaleye Management Inc. | 1,800,000 | new |
| Balyasny Asset Management L.P. | 1,686,575 | +1,276,796 |
| Qube Research & Technologies Ltd | 1,628,488 | +152,460 |
Insiders
12 insiders reported holding 1,378,348 shares in total, about $12M at the last price.
| Holder | Shares |
|---|---|
| Paterson DanPresident and CEO, Director | 651,413 |
| Stuglik Brian MDirector | 137,147 |
| Calkins DanielChief Financial Officer | 123,781 |
| Bailey Michael PDirector | 108,000 |
| Tollefson Karin AnnaDirector | 52,666 |
| Johnson JohnDirector | 52,666 |
| Kapur AnilDirector | 52,666 |
| Robertson MichelleDirector | 52,666 |
| Rowinsky Eric KDirector | 52,666 |
| Bunn Paul A.Director | 44,333 |
Questions about VSTM
What does Verastem, Inc. do?
Verastem, Inc. is a company in the Health care sector, listed on NASDAQ as VSTM. Its shares trade on NASDAQ under the ticker VSTM.
What is Verastem, Inc.'s net worth?
Verastem, Inc. has a market value (market cap) of $790.6M at the latest share price, and shareholders' equity of $10.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Verastem, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $178.9M.
When did Verastem, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Verastem, Inc.'s next earnings report?
Verastem, Inc.'s next report is expected around February 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VSTM with
Follow VSTM
Get an email when Verastem, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Verastem, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.